Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia [Yahoo! Finance]
Cellectar Biosciences, Inc. (CLRB)
Last cellectar biosciences, inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cellectar.com
Company Research
Source: Yahoo! Finance
FLORHAM PARK, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced two presentations: one regarding the treatment of a patient with Bing-Neel Syndrome (BNS), and a review of the company's CLOVER WaM pivotal study of iopofosine I 131 at the 12 th International Workshop on Waldenstrom's Macroglobulinemia being held October 17-19, 2024, in Prague, Czech Republic. BNS is a rare, life-threatening complication of WM that manifests in the central nervous system (CNS). It typically translates into various neurological sequalae, such as neuropathy, headaches, visual disturbances, changes in gait, partial paralysis and is associated with poor outcomes. Up to 30% of patients diagnosed with BNS die within the first three years of diagnosis. Cellectar's lead product candidate, iopofosine I 131, is a pot
Show less
Read more
Impact Snapshot
Event Time:
CLRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLRB alerts
High impacting Cellectar Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CLRB
News
- NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]Yahoo! Finance
- NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire
- Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate UpdateGlobeNewswire
CLRB
Earnings
- 11/18/24 - Miss
CLRB
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 10-Q
- 11/15/24 - Form 8-K
- CLRB's page on the SEC website